TeriNguyenKreislMD

Neurology • New York, NY

Neurooncology

Physician

Join to view full profile

Dr. Kreisl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kreisl's full profile

Already have an account?

Office
710 W 168th St
Rm 1125A
New York, NY 10032
Phone+1 212-342-0571

Fax+1 212-342-1246

Education & Training

New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 2001 - 2005
Weill Cornell MedicineClass of 2001

Certifications & Licensure

NY State Medical License 2003 - 2025
MD State Medical License 2012 - 2014
American Board of Psychiatry and Neurology Neurology

Clinical Trials

GW572016 to Treat Recurrent Malignant Brain Tumors Start of enrollment: 2005 Mar 30
Completed
Phase 2
Enzastaurin to Treat Recurrent Brain Tumor Start of enrollment: 2005 Apr 07
Terminated
Phase 1
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors Start of enrollment: 2005 Apr 01
Completed
Phase 2
ZD6474 to Treat Advanced Brain Cancer in Patients Start of enrollment: 2005 Dec 29
Completed
Phase 1
Sunitinib to Treat Recurrent Brain Cancer Start of enrollment: 2008 Jun 01
Terminated
Phase 2
A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes Start of enrollment: 2010 Nov 12
Terminated
(11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas Start of enrollment: 2011 Jan 13
Terminated
AZD7451 for Recurrent Gliomas Start of enrollment: 2011 Oct 05
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

81 citations
Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas
Fabio M. Iwamoto, Teri N. Kreisl, Lyndon Kim, J. Paul Duic, John A. Butman
Cancer. 2010-04-01
1212 citations
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl, Lyndon Kim, Kraig Moore, Paul Duic, Cheryl Royce
Journal of Clinical Oncology. 2009-02-10
2 citations
Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas: A Retrospective Observational Study.
Marissa Barbaro, Craig D. Blinderman, Fabio M. Iwamoto, Teri N. Kreisl, Mary Welch
Neurology. 2021-11-18

Press Mentions

In the Clinic-Glioblastoma: Tumor-Treating Fields Found to Prolong Survival in GlioblastomaFebruary 8th, 2018
In the Clinic-Glioblastoma Tumor-Treating Fields Found to Prolong Survival in GlioblastomaFebruary 8th, 2018